Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Tax Provisions (2024 - 2025)

Adma Biologics' Tax Provisions history spans 4 years, with the latest figure at $12.2 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 115.83% year-over-year to $12.2 million; the TTM value through Dec 2025 reached $35.7 million, up 149.65%, while the annual FY2025 figure was $35.7 million, 149.65% up from the prior year.
  • Tax Provisions reached $12.2 million in Q4 2025 per ADMA's latest filing, up from $11.1 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $12.2 million in Q4 2025 to a low of -$77.2 million in Q4 2024.